{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:21:59Z","timestamp":1720221719146},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.10.031","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T21:05:54Z","timestamp":1482440754000},"page":"A20-A23","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["European strategy for vaccine development against infectious diseases"],"prefix":"10.1016","volume":"35","author":[{"given":"Line","family":"Matthiessen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannu","family":"L\u00e5ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Klimathianaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finnian","family":"Hanrahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kersti\u00ebns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxandra","family":"Draghia-Akli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.031_b0005","unstructured":"WHO|Immunization coverage. [Internet] Available at <http:\/\/www.who.int\/mediacentre\/factsheets\/fs378\/en\/>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0010","unstructured":"The Innovative Medicines Initiative. [Internet] Available at <http:\/\/www.imi.europa.eu>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0015","unstructured":"EDCTP:Home. The European & developing countries clinical trials partnership. [Internet] Available at <http:\/\/www.edctp.org>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0020","unstructured":"ADITEC. Advanced immunization technologies. [Internet] Available at <http:\/\/www.aditecproject.eu>."},{"issue":"2","key":"10.1016\/j.vaccine.2016.10.031_b0025","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/infdis\/jiu079","article-title":"Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signalling in children","volume":"210","author":"Cao","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.031_b0030","unstructured":"NEWTBVAC [Internet] Available at: <http:\/\/cordis.europa.eu\/result\/rcn\/57315_en.html>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0035","unstructured":"HOOKVACc [Internet] Available at: <http:\/\/hookvac.eu\/>."},{"issue":"8","key":"10.1016\/j.vaccine.2016.10.031_b0040","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/mt.2016.83","article-title":"Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol Ther"},{"issue":"286","key":"10.1016\/j.vaccine.2016.10.031_b0045","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.vaccine.2016.10.031_b0050","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2016.10.031_b0055","unstructured":"ADVANCE [Internet] Available at: <http:\/\/advance-vaccines.eu\/>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0060","unstructured":"Home|Horizon Prizes-Research & Innovation-European Commission [Internet] Available at <http:\/\/ec.europa.eu\/research\/horizonprize\/index.cfm>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0065","unstructured":"CureVac [Internet] Available at: <http:\/\/www.curevac.com\/>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0070","unstructured":"World Health Organization. Global tuberculosis report 2015 [Internet] Available at: <http:\/\/www.who.int\/tb\/publications\/global_report\/en\/>."},{"issue":"43","key":"10.1016\/j.vaccine.2016.10.031_b0075","doi-asserted-by":"publisher","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact of cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries","volume":"111","author":"Knight","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2016.10.031_b0080","unstructured":"TBVAC2020-TBVI [Internet] Available at <http:\/\/www.tbvi.eu\/for-partners\/tbvac2020\/>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0085","unstructured":"EMI-TB-Home [Internet] Available at <http:\/\/www.emi-tb.org\/>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0090","unstructured":"EAVI2020 [Internet] Available at <http:\/\/www.eavi2020.eu\/>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0095","unstructured":"Hope-EHVA [Internet] Available at: <http:\/\/www.ehv-a.eu\/>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0100","unstructured":"[Internet] Available at <http:\/\/europa.eu\/rapid\/press-release_IP-14-1194_en.htm>."},{"key":"10.1016\/j.vaccine.2016.10.031_b0105","unstructured":"Global Public-Private Partnership Announces publication of positive Phase1 Data for Ebola Vaccine regimen in JAMA|Johnson & [Internet] Available at: <http:\/\/www.jnj.com\/news\/all\/Global-Public-Private-Partnership-Announces-Publication-of-Positive-Phase-1-Data-for-Ebola-Vaccine-Regimen-in-JAMA>."},{"issue":"15","key":"10.1016\/j.vaccine.2016.10.031_b0110","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus Type 26- and Modified Vaccinia Ankara-vectored ebola vaccines \u2013 a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.10.031_b0115","unstructured":"InnovFin Infectious Diseases [Internet] Available at <http:\/\/www.eib.org\/products\/blending\/innovfin\/products\/infectious-diseases.htm>."},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2016.10.031_b0120","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1002\/hep.22962","article-title":"Hepatitis B and hepatocellular carcinoma","volume":"49","author":"Bisceglie","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2016.10.031_b0125","unstructured":"Open innovation, open science, open to the world \u2013 a vision for Europe|Digital Single Market [Internet] Available at: <https:\/\/ec.europa.eu\/digital-single-market\/en\/news\/open-innovation-open-science-open-world-vision-europe>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16309525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T13:23:44Z","timestamp":1536153824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16309525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":25,"alternative-id":["S0264410X16309525"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European strategy for vaccine development against infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}